Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
China biotech inks $135M deal for remaining rights to vTv med
Having secured regional rights to vTv’s inflammation drug, Newsoara is fronting $20 million to take ownership of the clinical-stage asset globally.
James Waldron
Feb 2, 2026 10:10am
Roche continues RNA return with $1.7B deal for Sanegene drug
Feb 2, 2026 8:35am
AstraZeneca returns to China's CSPC for $18.5B obesity deal
Jan 30, 2026 4:50am
Moderna offloads late-stage rare disease drug for $50M upfront
Jan 30, 2026 4:14am
AI-driven Formation snaps up oral autoimmune asset in $500M play
Jan 29, 2026 1:20pm
Sanofi keeps mum on Denali pact after scrapping final RIPK1 drug
Jan 29, 2026 5:16am
